Core Insights - Avicanna Inc. has announced positive preclinical results for its novel Powder Drug Delivery System (PwdRx), which enhances the bioavailability and absorption of cannabinoids, and has filed a provisional patent application with the USPTO [1][2][6] Group 1: PwdRx Technology - The PwdRx platform addresses formulation challenges of lipophilic cannabinoids, improving water solubility, bioavailability, and onset of action [2][6] - In preclinical studies, PwdRx showed 74% higher bioavailability, 63% faster peak plasma levels, and 134% higher peak plasma concentration compared to MCT oil formulations [3][5] - The technology supports long-term stability and manufacturing versatility, allowing for scalable production in various formats such as tablets, capsules, and pouches [6] Group 2: Clinical Applications - The provisional patent covers the use of PwdRx in treating pain and inflammation-related conditions, including rheumatoid arthritis, osteoarthritis, neuropathic pain, fibromyalgia, migraine, and multiple sclerosis [6] - The platform aims to provide healthcare providers with greater flexibility in tailoring treatment options for patients [6] Group 3: Company Positioning - The advancement of the PwdRx platform strengthens Avicanna's intellectual property portfolio and positions the company as a leader in cannabinoid delivery technology [7] - Avicanna is focused on the commercialization of cannabinoid-based products and has developed over thirty proprietary products for the medical and pharmaceutical markets [8]